Search results
Results from the WOW.Com Content Network
A disease-modifying osteoarthritis drug (DMOAD) is a disease-modifying drug that would inhibit or even reverse the progression of osteoarthritis. [1] Since the main hallmark of osteoarthritis is cartilage loss, a typical DMOAD would prevent the loss of cartilage and potentially regenerate it.
[citation needed] More recently, the term has been used to indicate a drug that reduces the rate of damage to bone and cartilage. [ citation needed ] DMARDs can be further subdivided into traditional small molecular mass drugs synthesised chemically and newer "biological" agents produced through genetic engineering.
Pharmaceutical agents that will alter the natural history of disease progression by arresting joint structural change and ameliorating symptoms are termed as disease modifying therapy. [63] Therapies under investigation include the following: Strontium ranelate – may decrease degeneration in osteoarthritis and improve outcomes [202] [203]
1.09 Alkylating agents: Altretamine: PO Alkylates DNA. Recurrent or advanced ovarian cancer Myelosuppression, peripheral neuropathy, seizures and hepatotoxicity (rare). Bendamustine: IV: Alkylates DNA. Chronic lymphocytic leukaemia, mantle cell lymphoma and non-Hodgkin's lymphoma. Myelosuppression, hypokalaemia and tachycardia. Busulfan: IV, PO ...
This can improve your body composition (the ratio of muscle, bone, and body fat percentages in your body). Some examples of strength training: Squats. Push-ups. Planks. Lunges. Sit-ups.
Biological response modifiers (BRMs) are substances that modify immune responses.They can be endogenous (produced naturally within the body) or exogenous (as pharmaceutical drugs), and they can either enhance an immune response or suppress it.
"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." Sugar-sweetened beverages may increase your risk for heart disease and type 2 diabetes, new research ...
diagnostic agent Lendalizumab [41] mab: humanized: C5: Lenvervimab [5] mab: humanized: hepatitis B surfage antigen: hepatitis B Lenzilumab [6] mab: human: CSF2: chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia: Lerdelimumab [17] mab: human: TGF-β2: reduction of scarring after glaucoma surgery: Leronlimab [5] mab: humanized ...